FindTrial
Sign In

EFFECT OF FSH TREATMENT ON ANEUPLOIDIC RATE IN OLIGOASTENOZOOSPERMIC PATIENTS - ND

EFFECT OF FSH TREATMENT ON ANEUPLOIDIC RATE IN OLIGOASTENOZOOSPERMIC PATIENTS - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005397-31-IT
Enrollment
Unknown
Registered
2008-03-20
Start date
2007-08-21
Completion date
Unknown
Last updated
2014-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

couple infertility MedDRA version: 9.1 Level: SOC Classification code 10038604 Term: Reproductive system and breast disorders

Interventions

Trade Name: GONAL F Pharmaceutical Form: Solution for injection INN or Proposed INN: Follitropin alfa Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 150-

Sponsors

AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: severe male factor Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: female: age > 38; reduced ovarian reserve; endometriosis male: chromosomical and/or genic anomalies

Design outcomes

Primary

MeasureTime frame
Main Objective: decrease of aneuploidic rate by treatment;Secondary Objective: 1. increase of seminal parameters 2. increase of pregnancy rate;Primary end point(s): decrease of aneuploidic rate by treatment—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026